Ask AI
ProCE Banner Activity

Guide du patient sur les dernières avancées cliniques dans les nouvelles thérapies pour la leucémie lymphoïde chronique ou le lymphome lymphocytique petit réfractaire ou récidivant

PDF

Cette ressource conviviale pour les patients résume les principales conclusions et points de chaque étude sur la leucémie lymphoïde chronique ou le lymphome lymphocytique à petites cellules. Ces ressources condensent chaque étude en un document de communication destiné aux patients, téléchargeable, afin de préparer les patients et leurs fournisseurs de soins de santé à des conversations importantes de prise de décision partagée.

Released: April 16, 2026

Share

Provided by

Provided by Clinical Care Options, LLC dba Decera Clinical Education

ProCE Banner

Supporters

Supported by an educational grant from Lilly.

Lilly

Target Audience

This activity is intended for hematologists, oncologists, and other healthcare professionals caring for patients with relapsed/refractory CLL globally.

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Apply recently presented data to clinical practice to expand treatment options and enhance outcomes for patients with relapsed/refractory CLL

  • Appraise the potential clinical implications of new data on novel targeted and cellular therapies for treatment selection and sequencing in patients with relapsed/refractory CLL

  • Support effective shared decision-making through patient education and resources on the potential clinical implications of recently presented data for relapsed/refractory CLL

Disclosure

Primary Author

Benoit Tessoulin, MD, PhD: consultant/advisor/speaker: AbbVie, Gilead/Kite, Incyte, Lilly.